ArticleThoracic cancer2016
Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.
Article in Thoracic cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review.Medicina oral, patologia oral y cirugia bucal · 2020Pooled it
- Salivary biomarkers for cancer diagnosis: a meta-analysis.Annals of medicinePooled it
- Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.The Journal of molecular diagnostics : JMD · 2018Trial
- Enhanced Detection of Druggable Mutations in Non-Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue.JCO precision oncology · 2025Article
- Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023Review
- Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.International journal of molecular sciences · 2023Review
- Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement.Biopreservation and biobanking · 2022Article
- Circulating tumour DNA - looking beyond the blood.Nature reviews. Clinical oncology · 2022Review
- A novel method for extracting circulating cell-free DNA from whole blood samples and its utility in the non-invasive prenatal test.Prenatal diagnosis · 2022Article
- Saliva Diagnostics.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics.Biosensors & bioelectronics · 2022Review
- Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).Biosensors · 2021Review
- Oral Microbiota: A Major Player in the Diagnosis of Systemic Diseases.Diagnostics (Basel, Switzerland) · 2021Review
- DNA integrity in diagnosis of premalignant lesions.Medicina oral, patologia oral y cirugia bucal · 2021Article
- A narrative review of exploring potential salivary biomarkers in respiratory diseases: still on its way.Journal of thoracic disease · 2021Review
- A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic.Mediastinum (Hong Kong, China) · 2021Review
- Salivary Biomarkers in Lung Cancer.Mediators of inflammation · 2021Review
- Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.Cancers · 2020Article
- Longitudinal Monitoring ofFrontiers in oncology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundThis article describes a pilot study evaluating a novel liquid biopsy system for non-small cell lung cancer (NSCLC) patients. The electric field-induced release and measurement (EFIRM) method utilizes an electrochemical biosensor for detecting oncogenic mutations in biofluids.
methodsSaliva and plasma of 17 patients were collected from three cancer centers prior to and after surgical resection. The EFIRM method was then applied to the collected samples to assay for exon 19 deletion and p.L858 mutations. EFIRM results were compared with cobas results of exon 19 deletion and p.L858 mutation detection in cancer tissues.
resultsThe EFIRM method was found to detect exon 19 deletion with an area under the curve (AUC) of 1.0 in both saliva and plasma samples in lung cancer patients. For L858R mutation detection, the AUC of saliva was 1.0, while the AUC of plasma was 0.98. Strong correlations were also found between presurgery and post-surgery samples for both saliva (0.86 for exon 19 and 0.98 for L858R) and plasma (0.73 for exon 19 and 0.94 for L858R).
conclusionOur study demonstrates the feasibility of utilizing EFIRM to rapidly, non-invasively, and conveniently detect epidermal growth factor receptor mutations in the saliva of patients with NSCLC, with results corresponding perfectly with the results of cobas tissue genotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.